A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy

PHASE3CompletedINTERVENTIONAL
Enrollment

446

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

March 13, 2017

Conditions
Bronchoscopy
Interventions
DRUG

Remimazolam

For induction and maintenance of sedation

DRUG

Placebo

Inactive control arm

DRUG

Midazolam

For induction and maintenance of sedation

Trial Locations (14)

21287

The Johns Hopkins Center for Interventional and Pulmonary Care, Baltimore

23225

Pulmonary Associates of Richmond, Richmond

23298

Virginia Commonwealth University, Richmond

27157

Wake Forest Baptist Health, Winston-Salem

27599

Unc Division of Pulmonary and Critical Care, Chapel Hill

27710

Duke University, Durham

28374

Pinehurst Medical Clinic, Pinehurst

29303

S. Carolina Pharmaceutical Research, Spartanburg

29425

Medical University of South Carolina, Charleston

33511

Pab Clinical Research, Brandon

33573

Sun City Office, Sun City Center

46360

Laporte County Institute For Clinical Research, Michigan City

63110

Washington University School of Medicine/Barnes-Jewish Hospital, St Louis

98405

Multicare Institute For Research & Innovation, Tacoma

Sponsors
All Listed Sponsors
collaborator

Premier Research Group plc

UNKNOWN

lead

Paion UK Ltd.

INDUSTRY

NCT02296892 - A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy | Biotech Hunter | Biotech Hunter